MiNK Therapeutics (INKT) Non-Current Assets (2020 - 2026)
MiNK Therapeutics (INKT) posted Non-Current Assets of $354518.0 for Q1 2026, down 9.3% sequentially from $390869.0 in Q4 2025, and down 48.43% YoY from $687500.0 in Q1 2025.
MiNK Therapeutics (INKT) Non-Current Assets (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $354518.0 in Q1 2026.
- Quarterly Non-Current Assets fell 48.43% year-over-year to $354518.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 46.32% YoY) and the FY2025 annual result came in at $390869.0, down 46.67% from the prior year.
- Non-Current Assets slipped to $354518.0 in Q1 2026 per INKT's latest filing, from $390869.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.1 million in Q4 2022 and troughed at $354518.0 in Q1 2026.
- A 5-year average of $765039.9 and a median of $799522.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 75.89% in 2022, then tumbled 48.43% in 2026.
- Over 5 years, Non-Current Assets stood at $1.1 million in 2022, then slipped by 10.59% to $953977.0 in 2023, then decreased by 23.17% to $732929.0 in 2024, then tumbled by 46.67% to $390869.0 in 2025, then retreated by 9.3% to $354518.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $354518.0, $390869.0, and $429344.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | 318,474.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 318,474.00 |
| Mar 31, 2026 | 354,518.00 |
| Dec 31, 2025 | 390,869.00 |
| Sep 30, 2025 | 429,344.00 |
| Jun 30, 2025 | 473,215.00 |
| Mar 31, 2025 | 687,500.00 |
| Dec 31, 2024 | 732,929.00 |
| Sep 30, 2024 | 799,522.00 |
| Jun 30, 2024 | 849,957.00 |
| Mar 31, 2024 | 894,992.00 |
| Dec 31, 2023 | 953,977.00 |
| Sep 30, 2023 | 991,458.00 |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 803,128.00 |
| Jun 30, 2022 | 787,541.00 |
| Mar 31, 2022 | 665,212.00 |
| Dec 31, 2021 | 606,595.00 |
| Sep 30, 2021 | 635,887.00 |